{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:43:47Z","timestamp":1777963427951,"version":"3.51.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02892-7","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:02:06Z","timestamp":1714640526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis"],"prefix":"10.1007","volume":"316","author":[{"given":"Marielos I.","family":"Posada Posada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Beatrice","family":"Alora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinaida Taligare Vasconcelos","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"5","key":"2892_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/17425255.2022.2099835","volume":"18","author":"L Calabrese","year":"2022","unstructured":"Calabrese L, Chiricozzi A, De Simone C, Fossati F, D\u2019Amore A, Peris K (2022) Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert Opin Drug Metab Toxicol 18(5):347\u2013355. https:\/\/doi.org\/10.1080\/17425255.2022.2099835","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2892_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S, Keam SJ (2019) Upadacitinib: first approval. Drugs 79:1819\u20131828. https:\/\/doi.org\/10.1007\/s40265-019-01211-z","journal-title":"Drugs"},{"issue":"5","key":"2892_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s12325-023-02490-5","volume":"40","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, de Montjoye L, Baeck M (2023) Real-life effectiveness and tolerance of Upadacitinib for severe atopic dermatitis in adolescent and adult. Adv Ther 40(5):2509\u20132514. https:\/\/doi.org\/10.1007\/s12325-023-02490-5","journal-title":"Adv Ther"},{"issue":"7","key":"2892_CR4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/eji.202048922","volume":"51","author":"FR Spinelli","year":"2021","unstructured":"Spinelli FR, Meylan F, O\u2019Shea JJ, Gadina M (2021) JAK inhibitor: ten years after. Eur J Immunol 51(7):1615\u20131627. https:\/\/doi.org\/10.1002\/eji.202048922","journal-title":"Eur J Immunol"},{"issue":"23","key":"2892_CR5","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/jcm11236894","volume":"11","author":"A Makris","year":"2022","unstructured":"Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Agouridis AP (2022) The Effect of Upadacitinib on lipid Profile and Cardiovascular events: a Meta-analysis of Randomized controlled trials. J Clin Med 11(23):6894. https:\/\/doi.org\/10.3390\/jcm11236894","journal-title":"J Clin Med"},{"issue":"3","key":"2892_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312\u2013320. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870","journal-title":"Ann Rheum Dis"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02892-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:47:29Z","timestamp":1717494449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":6,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02892-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of Interest: Xinaida Taligare V. Lima is a researcher for Biogen, Horizon and Janssen. She is on the speaker\u2019s bureau of Abbvie, Janssen and Novartis. Maria Beatrice Alora is a clinical investigator for Pfizer, Inc. Abbvie, Concert Pharmaceuticals, Eli Lilly and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}